GENMAB AS            DK 1
GENMAB AS DK 1
Share · DK0010272202 · 565131 (XCSE)
Overview Financial Indicators
200,40 EUR
2,90 % 5,65 EUR
NASDAQ COPENHAGEN A/S (XFRA) · Current prices and charts at MoneyPeak
10.06.2025 17:44

Current Prices from GENMAB AS DK 1

ExchangeTickerCurrencyLast TradePriceDaily Change
XFRA: Frankfurt
Frankfurt
GE9.F
EUR
10.06.2025 17:44
200,40 EUR
194,75 EUR
+2,90 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 4,10 % 13,22 % -1,81 % -4,30 % -21,10 % -23,63 %

Company Profile for GENMAB AS DK 1 Share

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Invested Funds

The following funds have invested in: GENMAB AS DK 1 invested:

Fund
iShares MSCI Europe Health Care Sector UCITS ETF EUR (Acc)
Vol. in million
832,16
Percentage (%)
1,91 %
Fund
iShares MSCI Europe Mid Cap UCITS ETF EUR (Acc)
Vol. in million
1.158,01
Percentage (%)
1,35 %
Fund
iShares MSCI Europe Mid Cap UCITS ETF EUR (Dist)
Vol. in million
110,52
Percentage (%)
1,35 %
Fund
iShares Edge MSCI Europe Minimum Volatility UCITS ETF EUR (Dist)
Vol. in million
175,99
Percentage (%)
1,14 %
Fund
iShares MSCI Europe SRI UCITS ETF EUR (Dist)
Vol. in million
7.713,76
Percentage (%)
1,10 %

Company Data

Name GENMAB AS DK 1
Company Genmab A/S
Website https://www.genmab.com
Primary Exchange XCSE NASDAQ COPENHAGEN A/S
WKN 565131
ISIN DK0010272202
Asset Class Share
CEO Dr. Jan G.J. van de Winkel Ph.D.
Market Capitalization 11 Mrd.
Country Denmark
Currency EUR
Employees 2,7 T
Address Carl Jacobsens Vej 30, 2500 Copenhagen
IPO Date 2000-10-23

Ticker Symbols

Name Symbol
Frankfurt GE9.F

More Shares

Investors who GENMAB AS DK 1 hold also have the following shares in their portfolio:
21SHARES BITCETP OE
21SHARES BITCETP OE ETN
BIONTECH SE ADR
BIONTECH SE ADR Share
BK MONTREAL 2022
BK MONTREAL 2022 Bond
COMINAR REAL EST.INV. UTS
COMINAR REAL EST.INV. UTS Share
EUROFINS SCI.EO 0,01
EUROFINS SCI.EO 0,01 Share
FORTEC ELEKTRO.
FORTEC ELEKTRO. Share
HANNOVER RÜCK SE
HANNOVER RÜCK SE Share
INFINEON TECHNOLOGIESLOGIES AG
INFINEON TECHNOLOGIESLOGIES AG Share
NABALTEC AG
NABALTEC AG Share
UMICORE S.A. ACTIONS NOM.
UMICORE S.A. ACTIONS NOM. Share
WACKER NEUSON SE
WACKER NEUSON SE Share
XINYI SOLAR S
XINYI SOLAR S Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025